Icecure Medical Ltd. · NASDAQ:ICCM
Icecure Medical — Investor Presentation (July 2022)
27 slides from Icecure Medical's investor presentation, Jul 11, 2022
Slide 1: Freezing cancer in its tracks
Corporate Presentation | July 2022 Freezing cancer in its tracks (NASDAQ & TASE: ICCM) icecure - medical.com IceCure Medical enabling non-surgical, treatment of cancerous tumors Nasdaq & TASE: ICCM
Slide 2: Forward Looking Statement Disclaimer
Forward Looking Statement Disclaimer: IMPORTANT : The following applies to this document, the oral presentation of the information in this document by IceCure Medical Ltd . (the “Company”, “we” or “us”) and any question - and - answer session that will follow the oral presentation (collectively, the
Slide 3: Introducing ProSense Non-surgical Next-Generation Cryoablation Technology
Introducing ProSense® Non - surgical Next - Generation Cryoablation Technology Cryoablation is a minimally invasive image guided (US or CT) treatment that uses extreme cold to freeze and accurately destroy diseased tissue within the tumor zone IceCure’s flagship product ProSense® cryoablates tumors
Slide 4: Company Highlights
Regulatory approval in 14* countries including U.S. and Europe Company Highlights *China – system only †Estimated, according to Grand View Research, Inc. ( www.grandviewresearch.com/industry - analysis/tumor - ablation - market ) Data is for all tumor ablation technologies and indications, including
Slide 5: Tumor Ablation Market Opportunities
Tumor Ablation Market Opportunities †Estimated, according to Grand View Research, Inc. ( www.grandviewresearch.com/industry - analysis/tumor - ablation - market ) Data is for all tumor ablation technologies and indications, including heat ablation Cryoablation, RF, MW and others. The information her
Slide 6: Regulatory approvals worldwide
Regulatory approvals worldwide FDA Approval for general minimally - invasive cryoablation applications , specific indications including: Kidney, Liver, Neurology, Fibroadenoma FDA Breakthrough Devices Designation for T 1 invasive breast cancer and/or breast cancer not suitable for surgical alternati
Slide 7: Clinical evidence
Clinical evidence Kidney cancer : Israel ICE Secret Trial, 120 cases Initial results reported ** 45 small kidney masses (≤ 4 cm) treated in 42 patients at 1 year follow - up (average follow - up period was 18 . 2 months) Recurrence free rate was 93 % One serious adverse event was reported Lung cance
Slide 8: ProSense is Superior to Competing Thermal Ablation Technologies
ProSense is Superior to Competing Thermal Ablation Technologies Cryoablation IceCure ProSense® Thermal Ablation (Radiofrequency & Microwave) Pain Minimal to no pain* Very painful Anesthesia Local High amount to general Visualization Excellent contour under Ultrasound & CT Limited visualization Accur
Slide 9: ProSense - Advanced Cryoablation Technology
ProSense® - Advanced Cryoablation Technology Achieves rapid temperature decrease at the beginning of the freeze cycle Lower stable temperatures Rapid cooling Lower and more stable temperatures Larger lethal zone LN2 less expensive vs. Argon LN2’s lower pressure ideal for in office setting vs high pr
Slide 10: Breast Tumor Market Activities
Breast Tumor Market Activities 10 Nasdaq & TASE: ICCM
Slide 11: Challenges in Breast Cancer Surgery (Lumpectomy)
Challenges in Breast Cancer Surgery (Lumpectomy) • Cost • Cosmetic outcome • 14% - 20% of patients undergo re - excision after lumpectomy due to unclear margins* • Recovery time • Use of operating rooms places an additional strain on hospital resources * https://link.springer.com/article/10.1245/s10
Slide 12: ProSense - Value for All
ProSense® - Value for All *LN 2 , liquid nitrogen ** https://link.springer.com/article/ 10.1245 /s 10434 - 019 - 07247 - 5 ; https://ascopubs.org/doi/abs/ _suppl. /JCO. Patient Physician Insurer Healthcare Provider x LN 2 * - Maximum Efficacy x Non - surgical x Cosmetically Su
Slide 13: Unique Value Proposition ICE3: Landmark U.S. Breast Cancer Trial
Unique Value Proposition ICE 3 : Landmark U.S. Breast Cancer Trial Largest USA controlled multicenter clinical trial ever performed for LN 2 based cryoablation of small, low - risk, early - stage malignant breast tumors as an alternative to surgery Interim results presented in April 2021 ASBrS Meeti
Slide 14: ICE3: U.S. Breast Cancer Trial Delivers Interim Results
ICE 3 : U.S. Breast Cancer Trial Delivers Interim Results x Submitted a pre - submission package to FDA on November 24 , 2021 x Proposed an intended use for early - stage breast cancer and high risk to surgery x Suggested a De Novo classification, including a request for a sprint discussion under FD
Slide 15: Breast Cancer & Benign Tumors U.S. Strategy
Breast Cancer & Benign Tumors U.S. Strategy *BDD is not an FDA Approval, but a designation granted that can expedite the path to marketing clearance for the breast cance r i ndication **CPT or Current Procedural Terminology is a medical code used by physicians, health insurance companies and accredi
Slide 16: Breast Cancer - China Strategy
Breast Cancer - China Strategy * https://gco.iarc.fr/today/data/factsheets/populations/ 160 - china - fact - sheets.pdf Regulatory strategy x Console approved by the National Medical Products Administration (NMPA) x Initiated a registration process for the disposable probes, estimated end of 2022 x
Slide 17: Breast Cancer - Japan Terumo Agreement
Breast Cancer - Japan Terumo Agreement *As of February 2021 ** https://gco.iarc.fr/today/data/factsheets/populations/ 392 - japan - fact - sheets.pdf $ 29 B* market cap; $ 5.9 B annual revenue ( 2019 / 2020 ) Exclusive strategic distribution agreement with Terumo to accelerate commercialization of P
Slide 18: Fibroadenomas
FIBROADENOMAS 18 Nasdaq & TASE: ICCM
Slide 19: ProSense: Becoming the Standard in Fibroadenoma Therapy
ProSense®: Becoming the Standard in Fibroadenoma Therapy Overview of benign breast disease | Author: Michael S Sabel, MD, Section Editor: Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS , F RCS(C) | Deputy Editor: Wenliang Chen, MD, PhD Treating fibroadenomas successfully since clinical trials began in
Slide 20: Interventional Radiology
Kidney Cancer Lung Cancer Bone Cancer Liver Cancer Interventional Radiology Nasdaq & TASE: ICCM Nasdaq & TASE: ICCM
Slide 21: Interventional Radiology: Expanding Product Line
Interventional Radiology: Expanding Product Line *https://gco.iarc.fr/tomorrow/en/dataviz/isotype 488 K new cases of kidney cancer globally by 2025 * > 2.5 M new cases of lung cancer globally by 2025 * Over 500,000 new people each year are diagnosed with kidney, lung, liver and prostate cancer in th
Slide 22: Interventional Radiology - USA Strategy
Interventional Radiology - USA Strategy *CPT or Current Procedure Terminology is a medical code used by physicians, health insurance companies and accreditation orga niz ations ** American Cancer Society .s 6 Regulatory Strategy x FDA approval for general minimally - invasive cryoablation applicatio
Slide 23: Business Model – Revenue Generators
Business Model – Revenue Generators Console and consumable probe business model Direct sales and via distributors x Direct sales to hospitals, clinics and doctor offices x Reselling to distributors x Used as a mobile device in different hospitals, clinics, doctor offices in Europe Console related re
Slide 24: Well-Financed to Advance Commercialization of ProSense
2018 2019 2020 2021 $ 3.9 M $ 1.6 M $ 1. ϭ M $ 4.1 M Well - Financed to Advance Commercialization of ProSense ® In 2021 , raised $ 32 M (gross) in private placement and Nasdaq offering led by three accredited investors as well as the controlling shareholder of IceCure Total Sales (USD) Well position
Slide 25: Global Presence of IceCure Technology
Global Presence of IceCure Technology JAPAN HONG KONG THAILAND SINGAPORE AUSTRALIA ISRAEL HUNGARY ROMANIA GERMANY ITALY SPAIN UNITED STATES COSTA RICA SOUTH AFRICA CHINA INDIA TURKEY FRANCE TAIWAN POLAND NETHERLANDS Nasdaq & TASE: ICCM
Slide 26: Proven Leadership Team
Proven Leadership Team Ronen Tsimerman, CFO and COO Over 15 years ’ experience as a CFO of public and private companies Ron Mayron, Chairman of the Board Served for 20 years in several positions at Teva including as VP – Israel & Africa & CEO of Teva Israel Shay Levav, VP Clinical, Regulatory & QA N
Slide 27: Thank You
ProSense® Freezing Cancer In Its Tracks 27 EYAL Shamir – CEO E: eyals@icecure - medical.com Ronen Tsimerman – CFO/COO E: ronent@icecure - medical.com T: + 972 - 4 - 623 - 0333 THANK YOU Nasdaq & TASE: ICCM